Agro Bizz Prothioconazol EC 250

Primær information

  • Handelsnavn:
  • Agro Bizz Prothioconazol EC 250 Emulsionskoncentrat
  • Lægemiddelform:
  • Emulsionskoncentrat
  • Sammensætning:
  • 250 g/l prothioconazol
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Agro Bizz Prothioconazol EC 250 Emulsionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Udgået
  • Autorisationsnummer:
  • 645-6
  • Sidste ændring:
  • 08-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

20-4-2018

Pending EC decision:  Credelio, lotilaner, Opinion date: 19-Apr-2018

Pending EC decision: Credelio, lotilaner, Opinion date: 19-Apr-2018

Europe - EMA - European Medicines Agency

20-4-2018

Pending EC decision:  Alsitek, masitinib, Opinion date: 18-Apr-2018

Pending EC decision: Alsitek, masitinib, Opinion date: 18-Apr-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Pending EC decision: Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Prasugrel Mylan, prasugrel, Opinion date: 22-Mar-2018

Pending EC decision: Prasugrel Mylan, prasugrel, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Repatha, evolocumab, Opinion date: 22-Mar-2018

Pending EC decision: Repatha, evolocumab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Dexxience, betrixaban, Opinion date: 22-Mar-2018

Pending EC decision: Dexxience, betrixaban, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Rubraca, rucaparib, Opinion date: 22-Mar-2018

Pending EC decision: Rubraca, rucaparib, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Pending EC decision: Pemetrexed Krka, pemetrexed, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Timloze, abaloparatide, Opinion date: 22-Mar-2018

Pending EC decision: Timloze, abaloparatide, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Zessly, infliximab, Opinion date: 22-Mar-2018

Pending EC decision: Zessly, infliximab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Kanjinti, trastuzumab, Opinion date: 22-Mar-2018

Pending EC decision: Kanjinti, trastuzumab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Ivemend, fosaprepitant, Opinion date: 22-Mar-2018

Pending EC decision: Ivemend, fosaprepitant, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Pending EC decision: Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

16-3-2018

Pending EC decision:  Onsior, robenacoxib, Opinion date: 15-Mar-2018

Pending EC decision: Onsior, robenacoxib, Opinion date: 15-Mar-2018

Europe - EMA - European Medicines Agency

16-3-2018

Pending EC decision:  Semintra, telmisartan, Opinion date: 15-Mar-2018

Pending EC decision: Semintra, telmisartan, Opinion date: 15-Mar-2018

Europe - EMA - European Medicines Agency

1-3-2018

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

FDA - U.S. Food and Drug Administration

23-2-2018

Pending EC decision:  Alpivab, peramivir, Opinion date: 22-Feb-2018

Pending EC decision: Alpivab, peramivir, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Kineret, anakinra, Opinion date: 22-Feb-2018

Pending EC decision: Kineret, anakinra, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Isentress, raltegravir, Opinion date: 22-Feb-2018

Pending EC decision: Isentress, raltegravir, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Xgeva, denosumab, Opinion date: 22-Feb-2018

Pending EC decision: Xgeva, denosumab, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Mylotarg, gemtuzumab ozogamicin, Opinion date: 22-Feb-2018

Pending EC decision: Mylotarg, gemtuzumab ozogamicin, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Sutent, sunitinib, Opinion date: 22-Feb-2018

Pending EC decision: Sutent, sunitinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Nerlynx, neratinib, Opinion date: 22-Feb-2018

Pending EC decision: Nerlynx, neratinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Feraccru, ferric maltol, Opinion date: 22-Feb-2018

Pending EC decision: Feraccru, ferric maltol, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Pending EC decision: Amglidia, glibenclamide, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Bosulif, bosutinib, Opinion date: 22-Feb-2018

Pending EC decision: Bosulif, bosutinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-2-2018

Pending EC decision:  Lynparza, olaparib, Opinion date: 22-Feb-2018

Pending EC decision: Lynparza, olaparib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

16-2-2018

Pending EC decision:  Metacam, meloxicam, Opinion date: 15-Feb-2018

Pending EC decision: Metacam, meloxicam, Opinion date: 15-Feb-2018

Europe - EMA - European Medicines Agency

16-2-2018

Pending EC decision:  Clevor, ropinirole, Opinion date: 15-Feb-2018

Pending EC decision: Clevor, ropinirole, Opinion date: 15-Feb-2018

Europe - EMA - European Medicines Agency

26-1-2018

Pending EC decision:  Lamzede, velmanase alfa, Opinion date: 25-Jan-2018

Pending EC decision: Lamzede, velmanase alfa, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

26-1-2018

Pending EC decision:  Hemlibra, emicizumab, Opinion date: 25-Jan-2018

Pending EC decision: Hemlibra, emicizumab, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

26-1-2018

Pending EC decision:  Semglee, insulin glargine, Opinion date: 25-Jan-2018

Pending EC decision: Semglee, insulin glargine, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

26-1-2018

Pending EC decision:  EnCyzix, enclomifene, Opinion date: 25-Jan-2018

Pending EC decision: EnCyzix, enclomifene, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

26-1-2018

Pending EC decision:  Steglatro, ertugliflozin, Opinion date: 25-Jan-2018

Pending EC decision: Steglatro, ertugliflozin, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

19-1-2018

Pending EC decision:  Panacur AquaSol, fenbendazole, Opinion date: 18-Jan-2019

Pending EC decision: Panacur AquaSol, fenbendazole, Opinion date: 18-Jan-2019

Europe - EMA - European Medicines Agency

16-3-2018

Scientific guideline:  Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for

Scientific guideline: Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for

The European Medicines Agency is seeking stakeholder input on any information or data that may help its Committee for Medicinal Products for Veterinary Use (CVMP) to reach an opinion on consumer risk from using diethanolamine as an excipient in veterinary medicines for food-producing animals.

Europe - EMA - European Medicines Agency

16-3-2018

MRL pending EC decision:  Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits AA

MRL pending EC decision: Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits AA

On 15 March 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion recommending the amendment of the entry for diflubenzuron.

Europe - EMA - European Medicines Agency

16-3-2018

MRL pending EC decision:  Isoflurane - Summary opinion of the CVMP on the establishment of maximum residue limits

MRL pending EC decision: Isoflurane - Summary opinion of the CVMP on the establishment of maximum residue limits

On 15 March 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion2 recommending the establishment of MRLs for isoflurane in porcine species and amending the existing entry for Equidae.

Europe - EMA - European Medicines Agency

28-2-2018

Voltaren Gel vs. Naprosyn

Voltaren Gel vs. Naprosyn

Voltaren Gel (diclofenac sodium topical gel) and Naprosyn (naproxen; other brand names: EC-Naprosyn and Anaprox/Anaprox DS) are nonsteroidal anti-inflammatory drugs (NSAIDs) used to treat osteoarthritis joint pain.

US - RxList

31-1-2018

Scientific guideline:  Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

30-1-2018

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

Updated Date: Jan 30, 2018 EST

US - DailyMed